INBX Inhibrx Corp Company Short-Term Debt

Public company logo of Inhibrx Corp (INBX)

Inhibrx Biosciences develops modified protein therapeutics to combat oncology and orphan diseases, utilizing an engineering approach to enhance target precision. The company's production capacities are fully utilized, while the synthesis of clinical drugs is delegated to proven contractors. The current metric stands at 0.00. This chart of individual debt pricing, which assists in the basic asset valuation, is provided below.

INBX (Inhibrx Biosciences, Inc.) Company Short-Term Debts history from 07/04/2022 to 10/31/2026

Analytical breakdowns for Inhibrx Corp (INBX)

- stock price and consensus target price:
Stock Price Inhibrx Biosciences, Inc.|INBX - Average Forecast Price
- market capitalization data:
Market Value Inhibrx Biosciences, Inc.|INBX - Value Adjusted for Debt and Cash
- shareholders' equity book value data:
Book Value per Share Inhibrx Biosciences|INBX - Book Capitalization|Market Value to Book Value Ratio inhibrx.com|INBX - Aggregate Company Assets
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Inhibrx Biosciences|INBX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Inhibrx Biosciences|INBX - Company Cumulative Debt|Debt to Book Capitalization Ratio Inhibrx Biosciences, Inc.|INBX - Company Long-Term Indebtedness|Company Short-Term Debts Inhibrx Biosciences|Quick Liquidity inhibrx.com
- net income and valuation multiples indicators:
INBX - Company Net Income
Basic company analysis:INBX - Inhibrx Biosciences, Inc.
Flagship merchandise of Inhibrx Biosciences

An analysis of the capital structure allows for the separation of the fundamental stability of Inhibrx Biosciences (INBX) from share price volatility. This metric captures the aggregate of all liabilities with a maturity of less than twelve months. The dynamics of the company's short-term borrowings demonstrate current liquidity levels and the intensity of leverage utilization. Stable payments support complex logistics chains during the transportation of biological products, which ensures the continuity of clinical trials and the preservation of business profitability.

Direct competitors

Incyte - Company Short-Term Debts|Short-Term Debt Hutchison MediPharma|Nuvation Pharma (NUVB) - Company Short-Term Debt|Day One Biopharmaceuticals Inc - Company Short-Term Loans and Borrowings|MNPR (Monopar Therapeutics) - Company Short-Term Debts|Company Short-Term Debts I-Mab Inc.|Company Short-Term Debt Fennec Pharmaceuticals Inc. (FENC)|Company Short-Term Debt HRTX (herontx.com)|Nuvectis - Company Current Liabilities|Company Short-Term Loans and Borrowings CHRS|CRBP - Company Short-Term Debt|Short-Term Debt Cardiff Oncology, Inc.|BeyondSpring (BYSI) - Company Short-Term Debt|Company Short-Term Indebtedness BCAB|LIXT (Lixte Biotechnology Holdings) - Company Short-Term Debts|Company Current Liabilities Citius Pharma (CTXR)|Company Short-Term Debt Cellectar Biosciences (CLRB)|BLRX - Short-Term Debt|Company Short-Term Debt Can-Fite BioPharma Ltd. CANF|Aprea Therapeutics Inc. - Company Short-Term Debt|KZIA - Company Short-Term Debt|Short-Term Debt Silexion Therapeutics Corp|NCNA: Company Short-Term Debts|Short-Term Indebtedness chimerix.com CMRX|Company Current Liabilities CYCC|Short-Term Debt G1 Pharma GTHX|Company Current Liabilities KRON (Kronos Bio Corp)|KTRA (Kintara Pharma) - Company Short-Term Loans and Borrowings|Oncternal Therapeutics - Company Current Liabilities|Amount of Current Liabilities PRTG (portagebiotech.com)